Diana Elisa Díaz-Jiménez

Dr. Diana Elisa Díaz-Jiménez

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
JSJuan Antonio Suárez-Cuenca
Juan Antonio Suárez-Cuenca
DDDiana Elisa Díaz-Jiménez
Diana Elisa Díaz-Jiménez
JPJuan Antonio Pineda-Juárez
Juan Antonio Pineda-Juárez
AMAlondra Gissel Mendoza-Mota
Alondra Gissel Mendoza-Mota
OVOfelia Dinora Valencia-Aldana
Ofelia Dinora Valencia-Aldana
PMPaul Mondragon-Teran
Paul Mondragon-Teran
Background: Metabolic syndrome (MS) is a combination of comorbidities that increase pro-inflammatory cytokines (PIC) production, with subsequent body composition (BC) abnormalities and high cardiovascular risk. Treatment with diet and exercise has been suggested as possible non-pharmacological adjuvant treatment. Objective: To determine changes in BC and PIC in patients with MS after a Mediterranean-type diet (MedDiet) and/or isokinetic exercise (IE). Methods: A controlled randomized clinical trial was conducted at a third-level hospital in Mexico City. Intervention groups: G1: MedDiet + IE; G2: IE; G3: MedDiet; G4: control. Anthropometry, BC, and PIC were collected from the baseline and at 12 weeks post-intervention. MedDiet was estimated from a 24-h recall record. IE consisted of a standard high-intensity anaerobic exercise program. Results: Forty-two patients with MS aged 18–65 years old were included. The most frequent comorbidities were obesity, insulin resistance, and dyslipidemia. After 6 months of intervention, a significant reduction of resistin was observed within the IE group and MedDiet + IE, whereas the former group also showed an increase in adiponectin. Interventions of MedDiet and MedDiet + IE showed a decrease in IL-10. Regarding BC, all groups increased the resistance values in relation to the baseline but were lower than the control group. Conclusions: The results suggest that MedDiet and IE have a selective impact on pro-inflammatory mediators, while the combination of MedDiet and IE may induce only minor changes in BC.

14 February 2026 in Diseases
Verified
Journal Article
Open access
PDF file
JSJuan Antonio Suárez-Cuenca
Juan Antonio Suárez-Cuenca
PZPablo Zermeño-Ugalde
Pablo Zermeño-Ugalde
DDDiana Elisa Díaz-Jiménez
Diana Elisa Díaz-Jiménez
JPJuan Antonio Pineda-Juárez
Juan Antonio Pineda-Juárez
DCDeyanhira Palacios Colunga
Deyanhira Palacios Colunga
AMAlberto Melchor-López
Alberto Melchor-López
Background: Sarcopenia is a progressive muscle disorder associated with metabolic syndrome (MS), in which early impairments in muscle strength and quality precede muscle mass loss. Simple, non-invasive measures such as handgrip strength, estimated appendicular skeletal muscle mass (eASM), and phase angle (PA) may aid early detection, while adipokines link muscle dysfunction to metabolic regulation. Objective: In the present study, we aimed to evaluate the association between sarcopenia markers and PA in patients with MS. Methods: A cross-sectional study was conducted in patients with MS, at a third-level hospital in Mexico City. Sarcopenia was assessed by handgrip strength and eASM; body composition and PA were measured using bioelectrical impedance; and plasma adipokines were quantified by ELISA. Results: Seventy-four (mean age, 57.7 years; 75% female; BMI, 32.5 kg/m2) participants with MS were included. Handgrip strength correlated with eASM (r = 0.64; p < 0.01) and PA (rho = 0.43; p < 0.01), and eASM also correlated with PA (rho = 0.40; p < 0.01) and predicted higher PA values (OR = 2.74; p = 0.042). The sarcopenic subgroup had lower brachial circumference and plasma adiponectin. Conclusions: Sarcopenia is frequent in MS and associated with lower adiponectin, suggesting a vulnerable condition. Functional/structural markers of sarcopenia showed significant correlation with PA, whereas combined methods may enhance the early detection and management of muscle deterioration in metabolic disease.